Access to Information Requests Completed - August 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

Completed Requests

For the month of August 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2010-01049	All correspondence and media response lines for the Minister of Health related to tobacco warning labels/quit lines and contraband. (Sep 1, 2010 to Dec 17, 2010).	All disclosed	60
A-2011-00604	Reports submitted by every tobacco manufacturer and importer under subsection 16(2) of the Tobacco Reporting Regulations. (Jan 1, 2010 to Jun 30, 2010).	Disclosed in part	242
A-2011-01068	Information regarding the product Kripps Guggulipids, NPN 80027313 by Kripps Pharmacy Ltd.	Disclosed in part	69
A-2011-01387	All Internationally Trained Workers Initiative contribution agreements and their annexes in effect January 13, 2012.	Disclosed in part	1,062
A-2011-01592	Information regarding the product Truvada by Gilead Sciences Canada Inc.	Disclosed in part	427
A-2011-01608	Documents of consultation regarding the Proposed Improvements to Health Canada's Marihuana Medical Access Program.	Disclosed in part	276
A-2011-01697	Information regarding the product ONBREZ (Indacaterol Maleate), DIN 02376938 by Novartis Pharmaceuticals Canada Limited.	Disclosed in part	389
A-2011-01746	Information about the brand name 'Microban' which supposedly contains Triclosan.	Disclosed in part	69
A-2012-00036	All documents relating to the concentrations of herbicide residues and metabolites in livestock feeds, including novel feeds. (Apr 6, 2007 to Apr 5, 2012).	Disclosed in part	38
A-2012-00107	All documents regarding Syngenta Crop Protection Canada Incorporated in relation to the preparation of the table entitled List of Compensable Studies from the Horizon 240EC Herbicide (Reg No 24067) Database provided to United Phosphorus, Inc.	Disclosed in part	14
A-2012-00127	Information regarding the product SLEEP-EZE, DIN 02348608.	Disclosed in part	96
A-2012-00132	All correspondence with representatives of the Non-Smokers Rights Association. (Jan 1, 2011 to May 1, 2012).	Disclosed in part	132
A-2012-00143	Prescribing Information for the product Colchicine Tablets by Odan Laboratories Inc.	All disclosed	4
A-2012-00160	AER. Report number: 000380231.	Disclosed in part	11
A-2012-00161	AER. Report number: 000380233.	All disclosed	8
A-2012-00172	Product Monographs for the product Ratio-Ciprofloxacin, DINs 02246825, 02246826 and 02246827.	All disclosed	174
A-2012-00196	All documents regarding the funding for the Alberta health Services Tobacco Reduction Unit. (Jan 1, 2010 to May 10, 2012).	Disclosed in part	311
A-2012-00216	Contractor Report (and Associated Health Canada Information) on Indoor Air Quality Testing Conducted at 269 Laurier Avenue West, Ottawa, on March 8, 2012.	All disclosed	117
A-2012-00219	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the Yukon. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	22
A-2012-00220	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the Northwest Territories. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	29
A-2012-00221	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the Province of Quebec. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	46
A-2012-00222	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the province of Ontario. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	310
A-2012-00223	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	470
A-2012-00224	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the province of Saskatchewan. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	204
A-2012-00225	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the province of Alberta. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	629
A-2012-00226	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the province of British Columbia. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	212
A-2012-00227	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the province of New-Brunswick. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	32
A-2012-00228	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in Nunavut. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	16
A-2012-00229	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the province of Nova Scotia. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	20
A-2012-00230	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the province of Prince Edward Island. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	10
A-2012-00231	All audits related to overpayments or suspected overpayments to service providers through the Non-Insured Health Benefits program for businesses in the province of Newfoundland and Labrador. (Jan 1, 2009 to May 14, 2012).	Disclosed in part	28
A-2012-00235	All question period cards prepared for the Minister. (Jan 30, 2012 to Mar 16, 2012).	Disclosed in part	457
A-2012-00279	All Memos and/or Hospitality approval forms sent to the Deputy Minister seeking approval for the purchase of alcohol.	Disclosed in part	78
A-2012-00283	All question period cards prepared for the Minister. (Mar 26, 2012 to May 18, 2012).	Disclosed in part	366
A-2012-00312	AERs. Report numbers: 000379797, 000379798, 000379799 and 000379800.	Disclosed in part	4
A-2012-00376	AERs. Report numbers: 000352690, 000353323, 000353657, 000356054 and 000357033.	Disclosed in part	10
A-2012-00377	AERs. Report numbers: 000357914, 000363701, 000368908, 000369408 and 000370102.	Disclosed in part	19
A-2012-00403	All correspondence relating to the selection of external and/or internal advisors, members, participants, and/or consultants of the proposed Health Canada Health study on wind turbines.	Disclosed in part	91
A-2012-00412	Information regarding the product Yang Fortifier Tablets; Jian Yang Tablets, NPN 80016242 by Classical Remedia Ltd.	Disclosed in part	76
A-2012-00416	Documents concerning a two-tiered health care system or privatization of health care or private health care delivery. (Jan 1, 2012 to Jun 13, 2012).	Disclosed in part	647
A-2012-00421	Any correspondence that has reported experiencing adverse effects from exposure to wind turbines and/or wind energy projects. (Jan 1, 2009 to Jun 15, 2012).	Disclosed in part	250
A-2012-00488	Documents regarding the health effect of long-term / continual / chronic exposure to low level Radiofrequency (RF) energy. (Jan 1, 2005 to Jun 26, 2012).	No records exist	0
A-2012-00499	Report dated March 3, 2011, on the nursing services department workplace climate assessment.	All disclosed	4
A-2012-00506	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of June 2012.	Disclosed in part	37
A-2012-00507	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during June 2012.	All disclosed	2
A-2012-00508	All documents for methylenedioxypyrovalerone (MDPV) regarding Health Canada's intention to add MDVP to the Controlled Drugs and Substances Act.	Disclosed in part	724
A-2012-00509	All documents pertaining to the "Status Decision" for methylenedioxypyrovalerone (MDPV).	Disclosed in part	82
A-2012-00510	All documents concerning "Canada RC" relating to violation of some regulatory requirements surrounding research chemicals.	All disclosed	60
A-2012-00519	List of the individuals and organizations that responded to the last round of consultations pertaining to the New Classes of Practitioners Regulations under the Controlled Drugs and Substances Act, published in the Canada Gazette, Part 1, Volume 146, No. 18, May 5, 2012.	Disclosed in part	7
A-2012-00520	AERs for the product Avelox. Report numbers: 000403735 and 000405167.	Disclosed in part	2
A-2012-00521	AERs for the product Cipro. Report numbers: 000406177 and 000406134.	Disclosed in part	3
A-2012-00522	AERs for the product Gadovist. Report numbers: 000398406 and 000404912.	Disclosed in part	3
A-2012-00523	AERs for the product Magnevist. Report numbers: 000401964, 000404265 and 000404901.	Disclosed in part	7
A-2012-00524	AERs for the product Mirena. Report numbers: 000399269 and 000406116.	Disclosed in part	3
A-2012-00525	AERs for the product Yasmin. Report numbers: 000401199, 000403106 and 000403753.	Disclosed in part	3
A-2012-00526	AERs for the product Yaz. Report numbers: 000399849, 000404138 and 000406544.	Disclosed in part	5
A-2012-00528	AERs for the product Tecta. Report numbers: 000399184, 000400194, 000401065, 000401723, 000408964, 000410090, 000410811, 000411226 and 000424011.	Disclosed in part	10
A-2012-00530	AERs for the product Canesten. Report numbers: 000401726 and 000411842.	Disclosed in part	4
A-2012-00532	A list of inspections conducted under the Marijuana Medical Access Regulations.	Disclosed in part	2
A-2012-00533	Copy of the list of contract / service providers for the Employee Assistance Program for the Correctional Services Canada for Atlantic Canada.	Disclosed in part	34
A-2012-00537	AERs for the product Sinemet. Report numbers: 000380308 and 000384034.	Disclosed in part	2
A-2012-00540	AERs for the product Pneumovax 23. Report numbers: 000381196, 000382436, 000382474, 000382668, 000386791, 000395519, 000388770 and 000386801.	Disclosed in part	12
A-2012-00541	AERs for the product Fosamax. Report numbers: 000381625, 000381879, 000382214, 000386381, 000396369, 000389712, 000393456 and 000387182.	Disclosed in part	19
A-2012-00542	AERs for the product Singulair. Report numbers: 000382658, 000382504, 000388047, 000393292, 000397390 and 000398069.	Disclosed in part	9
A-2012-00544	AERs for the product Zostavax. Report numbers: 000397840, 000382944, 000383179, 000384174, 000384397, 000389124, 000391651, 000391679, 000392558, 000397817, 000397828 and 000382566.	Disclosed in part	17
A-2012-00545	AERs for the product Fasovance. Report numbers: 000382844, 000383558 and 000396196.	Disclosed in part	5
A-2012-00546	AER for the product Cancidas. Report number: 000382883.	Disclosed in part	3
A-2012-00547	AERs for the product Propecia. Report numbers: 000387217 and 000392786.	Disclosed in part	2
A-2012-00548	AERs for the product Ezetrol. Report numbers: 000391786 and 000388663.	Disclosed in part	2
A-2012-00549	AERs for the product Cosopt. Report numbers: 000388670 and 000397834.	Disclosed in part	2
A-2012-00550	AER for the product Januvia. Report number: 000392407.	Disclosed in part	1
A-2012-00551	AER for the product Invanz. Report number: 000396579.	Disclosed in part	3
A-2012-00552	AER for the product Maxalt. Report number: 000384751.	Disclosed in part	1
A-2012-00554	All receipts and itineraries for Minister Aglukkaq's international and domestic travel for enclosed trips (including Minister's Office staff). (Sep 2, 2011 to Dec 1, 2011).	Disclosed in part	217
A-2012-00561	All contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of June 2012.	Disclosed in part	42
A-2012-00564	AER for the product CanesOral. Report number: 000417521.	Disclosed in part	1
A-2012-00577	All information sent to/correspondence from the Minister about the upcoming study on the health effects of wind turbines. (May 2, 2011 to Jul 23, 2012).	Disclosed in part	150
A-2012-00583	The identity of people and/or companies or corporate entities that filed complaints about the harmful effects of wind turbines, which were taken into consideration and led to a study on the health effects of wind turbines.	No records exist	0
A-2012-00585	All documents generated from inspections conducted under the Marijuana Medical Access Regulations regarding a person who is a holder of an authorization to possess or licence to produce. (Jul 24, 2009 to Jul 23, 2012).	Disclosed in part	532
A-2012-00586	List of public complaints, and any reports of this to the Minister, regarding a person who is a holder of an authorization to possess or licence to produce with respect to their possession or production of marijuana. (Jul 24, 2009 to Jul 23, 2012).	Disclosed in part	19
A-2012-00591	AER for the product Angeliq. Report number: 000407645.	Disclosed in part	1
A-2012-00593	AERs for the product Cipro. Report numbers: 000410350, 000412805 and 000414032.	Disclosed in part	3
A-2012-00594	AER for the product Diane-35. Report number: 000407291.	Disclosed in part	1
A-2012-00595	AERs for the product Magnevist. Report numbers: 000409909 and 000410060.	Disclosed in part	3
A-2012-00596	AERs for the product Gadovist. Report numbers: 000409392 and 000414317.	Disclosed in part	3
A-2012-00597	AERs for the product Mirena. Report numbers: 000407988 and 000410017.	Disclosed in part	3
A-2012-00598	AER for the product Xarelto. Report number: 000410417.	Disclosed in part	2
A-2012-00599	AERs for the product Yasmin. Report numbers: 000410011, 000411794 and 000414692.	Disclosed in part	5
A-2012-00600	AERs for the product Yaz. Report numbers: 000411795 and 000413961.	Disclosed in part	3
A-2012-00610	Bilateral reciprocal billing agreements between provinces and territories.	No records exist	0
A-2012-00612	The agreement between Health Canada and Truehope.	No records exist	0
A-2012-00613	A listing of the Access to Information requests submitted to Health Canada. (Jun 1, 2012 to Jun 30, 2012).	Disclosed in part	11
A-2012-00614	All communication between Health Canada and Truehope. (Jan 1, 2010 to Jul 17, 2012).	All excluded	0
A-2012-00618	AER. Report number: 000395506.	All disclosed	1
A-2012-00619	AER. Report number: 000382854.	Disclosed in part	1
A-2012-00620	AER. Report number: 000385397.	Disclosed in part	1
A-2012-00621	AER. Report number: 000382307.	Disclosed in part	2
A-2012-00622	AER. Report number: 000382857.	Disclosed in part	1
A-2012-00624	All documents to the Minister, regarding wind turbine noise and the wind turbine noise health study announced by health Canada on July 10, 2012.	Disclosed in part	46
A-2012-00625	Information regarding the product Natural Health Product Corectin by Constab International Inc.	All exempted	0
A-2012-00628	List of all the companies with active Natural Health Product site licences.	All excluded	0
A-2012-00632	All documents regarding the consideration and approval of a product monograph change for product Tysabri on May 23, 2012.	No records exist	0
A-2012-00639	AERs for the product Celexa. Report numbers: 000401715, 000414571, 000415211, 000420447, 000423174 and 000424367.	Disclosed in part	7
A-2012-00642	AER for the product Fluanxol. Report number: 000423009.	Disclosed in part	1
A-2012-00644	AER for the product Novir. Report number: 000375180.	Disclosed in part	1
A-2012-00646	The generic and trade names of all new active substances approved in fiscal year 2011-2012 that were approved either over target or 0-7 days under target.	No records exist	0
A-2012-00647	AERs for the product Ultiva. Report numbers: 00044030, 000440034, 000440036, 000440040, 000440043, 000440045, 000440048 and 000440054.	Disclosed in part	8
A-2012-00648	AERs for the product Ulitiva. Report numbers: 000440058, 000440063, 000440067, 000440079, 000440087, 000440091, 000440096 and 000440972.	Disclosed in part	8
A-2012-00656	All briefing notes on the presence of arsenic in fruit juices and nectars in Canada. (Jan 1, 2011 to Jul 1, 2012).	All disclosed	4
A-2012-00657	All briefing notes to the Minister and/or Deputy Minister from October 1, 2011 to July 1, 2012, regarding the Auditor General's report tabled on November 22, 2012.	No records exist	0
A-2012-00660	Product Monograph for the products ESME 21 and ESME 28 by Famy Care Ltd.	All exempted	0
A-2012-00663	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Task and Solutions Professional Services during the period of May and June 2012.	Disclosed in part	7
A-2012-00666	All MedEffect Canada documents, press releases, and other similar documents and related correspondence concerning Cipralex and/or generic version of Cipralex. (Jan 1, 2005 to Aug 17, 2012).	No records exist	0
A-2012-00673	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of July 2012.	Disclosed in part	46
A-2012-00676	All documents regarding people who suffered serious adverse effects after receiving one or more vaccines from health care specialists in Canada. (Jan 1, 2005 to Jul 31, 2012).	No records exist	0
A-2012-00683	All documents created in preparation of the meeting held on May 18, 2011 between the Victorian order of Nurses and Health Canada.	No records exist	0
A-2012-00687	All documents created in preparation of the meeting held on November 23, 2011 between the Canadian Beverage Association and the Minister.	No records exist	0
A-2012-00688	All documents created in preparation of the meeting held on February 25, 2011 between the Canadian Beverage Association and Health Canada.	No records exist	0
A-2012-00695	All MedEffect Canada documents, press releases, and other similar documents and related correspondence concerning, Prozac and/or generic version of Prozac. (Jan 1, 2005 to Aug 17, 2012).	No records exist	0
A-2012-00696	All MedEffect Canada documents, press releases, and other similar documents and related correspondence concerning Zoloft and/or generic version of Zoloft. (Jan 1, 2005 to Aug 17, 2012).	No records exist	0
A-2012-00794	Copies of all reciprocal Interprovincial health agreements between all provinces (except Quebec).	No records exist	0
A-2012-00807	Any government information about Health Canada warnings about the danger of daily doses of 30 mg or more of Olanzapine (also known as zyprexa) zydis. (Jan 1, 2005 to Aug 16, 2012).	No records exist	0